ArticleCritical care (London, England)2020
Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients.
Article in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04901169 (Angiotensin II in Liver Transplantation), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Angiotensin II in Liver Transplantation (AngLT-1): A Pilot Randomized Controlled Trial
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Association of the abbreviated burn severity index with mortality in severely burned patients: A meta-analysis.PloS one · 2025Pooled it
- Circulating dipeptidyl peptidase 3 and outcomes in acute heart failure: an analysis of the STRONG-HF and CORTAHF studies.ESC heart failure · 2026Trial
- Article
- Dipeptidyl peptidase 3 sets the threshold for immune activation and survival during experimental bacterial infection.Nature communications · 2026Article
- Novel aspects of the renin-angiotensin-aldosterone system in septic shock.Current opinion in physiology · 2026Article
- The short-term and long-term effect of burn on organ dysfunction: mechanisms and strategies.Frontiers in immunology · 2026Review
- What is new in burn shock resuscitation?Intensive care medicine · 2025Article
- Elevated circulating dipeptidyl peptidase 3 (cDPP3) as a predictor of postoperative complications in esophagectomy patients.Langenbeck's archives of surgery · 2025Article
- Vasoactive Agents in Burn Patients: Perspectives on Angiotensin-II.Journal of burn care & research : official publication of the American Burn Association · 2025Review
- Targeting high circulating dipeptidyl peptidase 3 in circulatory failure.Critical care (London, England) · 2025Review
- Bio-Adrenomedullin and Dipeptidyl Peptidase 3 as Novel Sepsis Biomarkers in the Emergency Department and the Intensive Care Unit: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Current and novel biomarkers in cardiogenic shock.European journal of heart failure · 2025Review
- Shock prediction with dipeptidyl peptidase-3 and renin (SPiDeR) in hypoxemic patients with COVID-19.Journal of critical care · 2025Article
- Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin Peptides.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Acute kidney injury in patients with burns.Nature reviews. Nephrology · 2024Review
- Dipeptidyl-peptidase 3 and IL-6: potential biomarkers for diagnostics in COVID-19 and association with pulmonary infiltrates.Clinical and experimental medicine · 2023Observational
- The alternative renin-angiotensin system in critically ill patients: pathophysiology and therapeutic implications.Critical care (London, England) · 2023Review
- Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study.ERJ open research · 2023Article
- Dipeptidyl Peptidase 3 Activity as a Promising Biomarker of Bone Fragility in Postmenopausal Women.Molecules (Basel, Switzerland) · 2022Article
- DPP3: From biomarker to therapeutic target of cardiovascular diseases.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundDipeptidyl peptidase-3 (DPP3) is a metallopeptidase which cleaves bioactive peptides, notably angiotensin II, and is involved in inflammation regulation. DPP3 has been proposed to be a myocardial depressant factor and to be involved in circulatory failure in acute illnesses, possibly due to angiotensin II cleavage. In this study, we evaluated the association between plasmatic DPP3 level and outcome (mortality and hemodynamic failure) in severely ill burn patients.
methodsIn this biomarker analysis of a prospective cohort study, we included severely ill adult burn patients in two tertiary burn intensive care units. DPP3 was measured at admission (DPP3
resultsOne hundred and eleven consecutive patients were enrolled. The median age was 48 (32.5-63) years, with a median total body surface area burned of 35% (25-53.5) and Abbreviated Burn Severity Index (ABSI) of 8 (7-11). Ninety-day mortality was 32%. The median DPP3
conclusionsPlasma DPP3 concentration at admission was associated with an increased risk of death, circulatory failure, and AKI in severely burned patients. Whether DPP3 plasma levels could identify patients who would respond to alternative hemodynamic support strategies, such as intravenous angiotensin II, should be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.